NCT02117115View on ClinicalTrials.gov

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

May 31, 2015

Conditions
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, ChronicMultiple Myeloma
Interventions
RADIATION

Dynamic contrast-enhanced computed tomography

CT scan performed between Day +7 and Day +14.

DRUG

Ioversol

To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02117115 - Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter